Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALAI.L Regulatory News (ALAI)

  • There is currently no data for ALAI

Edison issues review on Aberdeen Latin American

20 Aug 2021 08:00

RNS Number : 2244J
Aberdeen Latin American Inc Fd Ltd
20 August 2021
 

 

London, UK, 20 August 2021

 

Edison issues review on Aberdeen Latin American Income Fund (ALAI)

Aberdeen Latin American Income Fund's (ALAI) managers at Aberdeen Standard Investments (ASI) are encouraged by the prospects for Latin America. An economic recovery is underway and is spreading from the industrial to the service sectors as the COVID-19 vaccination programme in the region gains momentum. While inflationary pressures are building, the managers are hopeful that central banks' monetary policies will ensure that these are temporary; for example, in Brazil, interest rates have already been hiked four times this year. The managers say that the Latin American stock market is supported by a strong earnings recovery, helped by higher commodity prices and attractive valuations. Their optimism is reflected in ALAI's higher equity weighting, which now makes up around two-thirds of the fund.

ALAI's current 10.8% share price discount to cum-income NAV compares with the 12.0% to 13.5% range of average discounts over the last one, three and five years. There is scope for a higher valuation if investor sentiment towards Latin American equities improves, as over the last 12 months the discount narrowed to 3.1% (in March 2021), which was a five-year low. Despite lower levels of income, the company has continued to pay regular quarterly dividends, using revenue reserves when required; it currently yields 6.4%.

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5720 investmenttrusts@edisongroup.com

Sarah Godfrey +44 (0)20 3681 2519 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-/

Twitter www.twitter.com/Edison_Inv_Res 

YouTube www.youtube.com/edisonitv

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADKCBPQBKDBFD
Date   Source Headline
13th Jun 20236:00 pmRNSAbrdn Latin American Income Fund
12th Jun 20231:05 pmRNSResult of EGM
12th Jun 20237:30 amRNSSuspension-abrdn Latin American Income Fund
9th Jun 202312:35 pmRNSNet Asset Value(s)
9th Jun 202310:33 amRNSRepayment and Cancellation of Loan Facility
8th Jun 202312:45 pmRNSNet Asset Value(s)
7th Jun 20234:46 pmRNSHolding(s) in Company
7th Jun 202312:01 pmRNSNet Asset Value(s)
7th Jun 202310:55 amRNSMonth End Net Asset Value(s)
6th Jun 202312:13 pmRNSNet Asset Value(s)
5th Jun 20234:18 pmRNSNet Asset Value(s)
2nd Jun 20233:39 pmRNSQuarterly disclosure
2nd Jun 20231:22 pmRNSNet Asset Value(s)
31st May 20231:28 pmRNSNet Asset Value(s)
30th May 20233:54 pmRNSGearing disclosure
30th May 20233:47 pmRNSHolding(s) in Company
30th May 202312:51 pmRNSNet Asset Value(s)
26th May 202312:38 pmRNSNet Asset Value(s)
25th May 20233:55 pmRNSHolding(s) in Company
25th May 202312:34 pmRNSNet Asset Value(s)
24th May 202311:59 amRNSNet Asset Value(s)
23rd May 202312:21 pmRNSNet Asset Value(s)
22nd May 20233:21 pmRNSGearing disclosure
22nd May 202312:25 pmRNSNet Asset Value(s)
19th May 20231:49 pmRNSNet Asset Value(s)
18th May 202312:50 pmRNSNet Asset Value(s)
18th May 202310:14 amRNSPortfolio disclosure
18th May 20237:00 amRNSRecommended Proposals for Winding-Up of Company
17th May 202312:37 pmRNSNet Asset Value(s)
16th May 202312:06 pmRNSNet Asset Value(s)
15th May 20232:55 pmRNSGearing disclosure
15th May 202311:41 amRNSNet Asset Value(s)
12th May 202312:14 pmRNSNet Asset Value(s)
11th May 202312:35 pmRNSNet Asset Value(s)
11th May 202311:57 amRNSHolding(s) in Company
10th May 20231:07 pmRNSNet Asset Value(s)
9th May 20235:38 pmRNSGearing disclosure
9th May 202311:53 amRNSNet Asset Value(s)
5th May 20236:15 pmRNSMonth End Net Asset Value(s)
5th May 20231:12 pmRNSNet Asset Value(s)
4th May 202312:36 pmRNSNet Asset Value(s)
3rd May 202312:44 pmRNSNet Asset Value(s)
2nd May 20234:05 pmRNSGearing disclosure
28th Apr 20231:00 pmRNSNet Asset Value(s)
27th Apr 20231:17 pmRNSNet Asset Value(s)
26th Apr 20231:12 pmRNSNet Asset Value(s)
25th Apr 202312:45 pmRNSNet Asset Value(s)
24th Apr 20232:26 pmRNSGearing disclosure
24th Apr 202312:19 pmRNSNet Asset Value(s)
21st Apr 202312:58 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.